ELEV [NASD]
Elevation Oncology, Inc.
Index- P/E- EPS (ttm)-4.06 Insider Own0.10% Shs Outstand23.29M Perf Week9.00%
Market Cap25.20M Forward P/E- EPS next Y-2.31 Insider Trans0.00% Shs Float22.79M Perf Month45.33%
Income-85.70M PEG- EPS next Q-0.78 Inst Own73.00% Short Float / Ratio0.15% / 0.43 Perf Quarter14.54%
Sales- P/S- EPS this Y-248.60% Inst Trans-5.93% Short Interest0.03M Perf Half Y-14.84%
Book/sh2.88 P/B0.37 EPS next Y42.40% ROA-66.00% Target Price4.17 Perf Year-71.87%
Cash/sh4.54 P/C0.23 EPS next 5Y- ROE-78.50% 52W Range0.72 - 5.20 Perf YTD14.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-79.04% Beta-
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low50.78% ATR0.09
Employees48 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)55.51 Volatility6.33% 11.24%
OptionableNo Debt/Eq0.44 EPS Q/Q-215.70% Profit Margin- Rel Volume3.23 Prev Close1.06
ShortableYes LT Debt/Eq0.44 Earnings- Payout- Avg Volume78.96K Price1.09
Recom2.40 SMA206.27% SMA5010.41% SMA200-25.08% Volume98,964 Change2.83%
Dec-23-21Initiated H.C. Wainwright Buy $12
Jan-09-23 07:30AM
Jan-06-23 08:15AM
Nov-30-22 07:30AM
Nov-03-22 07:30AM
Aug-12-22 09:30AM
07:30AM Loading…
Aug-04-22 07:30AM
Aug-03-22 08:00AM
Jul-28-22 08:50AM
08:45AM
Jul-14-22 08:45AM
Jun-01-22 07:30AM
May-26-22 05:05PM
08:27AM
May-25-22 07:30AM
May-05-22 07:30AM
10:05AM Loading…
Apr-27-22 10:05AM
Mar-24-22 01:12PM
Mar-14-22 07:00AM
Mar-03-22 07:30AM
Mar-01-22 07:00AM
Jan-10-22 07:00AM
Jan-06-22 08:00AM
Jan-05-22 08:00AM
Dec-16-21 09:14AM
Nov-18-21 08:00AM
Nov-12-21 07:30AM
Oct-20-21 07:00AM
Oct-14-21 07:00AM
Sep-25-21 09:52AM
Sep-07-21 07:00AM
04:05PM Loading…
Aug-12-21 04:05PM
Aug-04-21 07:00AM
Jun-24-21 08:44PM
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
venBio Global Strategic Fund I10% OwnerMay 25Sale4.12702,7372,897,8061,905,430May 27 07:20 PM